Contact PD/PI: Buchanan, Thomas A UL1 ABSTRACT The Southern California Clinical and Translational Science Institute (SC CTSI) is a multidisciplinary research institute housed at the University of Southern California and Children's Hospital Los Angeles. In partnership with the Los Angeles County Department of Health Services and broad based community health organizations throughout Los Angeles, SC CTSI seeks to be a leader in engaging diverse communities and special populations in clinical and translational research to improve their health. SC CTSI It is led by a team of experienced faculty and staff members who have deep experience in developing and supporting clinical and translational research. They propose to address issues of health across the lifespan, as well as challenges in clinical and translational research, by pursuing five specific aims are: (1) Engage diverse communities and special populations, their care providers and our researchers to establish clinical research priorities; identify barriers to research participation; and develop, demonstrate and disseminate innovative approaches to assure fully partnered clinical research across diverse communities and the lifespan; (2) Promote team science in clinical research by assembling interdisciplinary teams, including community members, to collaboratively design and conduct clinical studies and develop innovative approaches to address challenges in clinical research; (3) Expand workforce capacity and capabilities by training researchers, staff, and clinical and community partners in team-based research in diverse and special populations; (4) Streamline clinical research processes and create efficient systems to support safe and effective conduct of high quality local and multicenter clinical research, in particular in diverse clinical and community settings; and (5) Participate as an exemplary CTSA hub, conduct multi-site network studies, adopt successful models from CTSA peers and develop and disseminate innovative strategies throughout the CTSA network. We also bring special strengths in engaging diverse communities, digital innovation, and regulatory science to develop new approaches to overcome challenges in clinical research. Success in achieving our aims will create new solutions for health problems affecting some of the fasting growing and most vulnerable special populations in America, define new approaches to research with diverse communities, and contribute our deep experience and expertise to the national CTSA network. Project Summary/Abstract Page 73 Contact PD/PI: Buchanan, Thomas A UL1

Public Health Relevance

This application is for support of the Southern California Clinical and Translational Science Institute (SC CTSI). The SC CTSI is a multi-disciplinary institute housed at the University of Southern California and Children's Hospital Los Angeles. In partnership with the Los Angeles County Department of Health Services and broad based community health organizations in Los Angeles, the SC CTSI seeks to develop and support multidisciplinary clinical and translational research that will improve the health of diverse communities and address challenges in the conduct of clinical research with those communities. Project Narrative Page 74

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1TR001855-02
Application #
9308040
Study Section
Special Emphasis Panel (ZTR1-SRC (99))
Program Officer
Jones, Patricia L
Project Start
2016-07-01
Project End
2021-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
2
Fiscal Year
2017
Total Cost
$7,034,914
Indirect Cost
$2,418,122
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90033
Konis, Kyle; Mack, Wendy J; Schneider, Edward L (2018) Pilot study to examine the effects of indoor daylight exposure on depression and other neuropsychiatric symptoms in people living with dementia in long-term care communities. Clin Interv Aging 13:1071-1077
Dieli-Conwright, Christina M; Courneya, Kerry S; Demark-Wahnefried, Wendy et al. (2018) Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial. J Clin Oncol 36:875-883
Xiang, Anny H; Trigo, Enrique; Martinez, Mayra et al. (2018) Impact of Gastric Banding Versus Metformin on ?-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. Diabetes Care 41:2544-2551
Dieli-Conwright, Christina M; Courneya, Kerry S; Demark-Wahnefried, Wendy et al. (2018) Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial. Breast Cancer Res 20:124
Bhalla, Anoopindar K; Yehya, Nadir; Mack, Wendy J et al. (2018) The Association Between Inhaled Nitric Oxide Treatment and ICU Mortality and 28-Day Ventilator-Free Days in Pediatric Acute Respiratory Distress Syndrome. Crit Care Med 46:1803-1810
Dawson, Jacqueline K; Dorff, Tanya B; Todd Schroeder, E et al. (2018) Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer 18:368
Azevedo, Christina J; Cen, Steven Y; Khadka, Sankalpa et al. (2018) Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol 83:223-234
Gutierrez, Lucas; Jang, Miran; Zhang, Tian et al. (2018) Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia. Sci Rep 8:17544
Nagoshi, Makoto; Reddy, Swayta; Bell, Marisa et al. (2018) Low-dose dexmedetomidine as an adjuvant to propofol infusion for children in MRI: A double-cohort study. Paediatr Anaesth 28:639-646
Lang, Julie E; Ring, Alexander; Porras, Tania et al. (2018) RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer. Ann Surg Oncol 25:2261-2270

Showing the most recent 10 out of 54 publications